Abstract Activated a5b1 integrin occurs specifically on tumor cells and on endothelial cells of tumor-associated vasculature, and plays a key role in invasion and metastasis. The PHSCN peptide (Ac-PHSCN-NH 2 ) preferentially binds activated a5b1, to block invasion in vitro, and inhibit growth, metastasis and tumor recurrence in preclinical models of prostate cancer. In Phase I clinical trial, systemic Ac-PHSCN-NH 2 monotherapy was well tolerated, and metastatic disease progression was prevented for 4-14 months in one-third of treated patients. We have developed a significantly more potent derivative, the PHSCN-polylysine dendrimer (Ac-PHSCNGGK-MAP). Using in vitro invasion assays with naturally serum-free basement membranes, we observed that the PHSCN dendrimer was 130-to 1900-fold more potent than the PHSCN peptide at blocking a5b1-mediated invasion by DU 145 and PC-3 human prostate cancer cells, whether invasion was induced by serum, or by the Ac-PHSRN-NH 2 peptide, under serum-free conditions. The PHSCN dendrimer was also approximately 800 times more effective than PHSCN peptide at preventing DU 145 and PC-3 extravasation in the lungs of athymic mice. Chou-Talalay analysis suggested that inhibition of both invasion in vitro and extravasation in vivo by the PHSCN dendrimer are highly synergistic. We found that many extravasated DU 145 and PC-3 cells go onto develop into metastatic colonies, and that a single pretreatment with the PHSCN dendrimer was 100-fold more affective than the PHSCN peptide at reducing lung colony formation. Since many patients newly diagnosed with prostate cancer already have locally advanced or metastatic disease, the availability of a welltolerated, nontoxic systemic therapy, like the PHSCN dendrimer, which prevents metastatic progression by inhibiting invasion, could be very beneficial. 
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Introduction
Invasion is key to prostate cancer metastasis because it promotes tumorigenesis by supporting endothelial cell invasion and neovascularization [1] , as well as enabling tumor cells to invade the tissue surrounding a tumor, enter the circulatory system, and extravasate at distant sites to form metastatic colonies [2, 3] . Thus, unrestricted invasion is a very important, debilitating aspect of the metastatic phenotype [4] . Extravasation is a key step in hematogenous cancer metastasis [5] , occurring after tumor cells arrest in microvasculature or sinusoids. Tumor cell arrest may occur by trapping without stable adhesion [6] , or may involve preferential adhesion to the endothelial cells of specific sites [7] . After arrest and transit of the endothelial cell layer, invasion of the underlying basement membrane is required for completion of extravasation, and entry into interstitial connective tissue [5] .
We have devised a peptide of 5 amino acids that is a potent inhibitor of a5b1 integrin-mediated invasion by prostate cancer cells. The acetylated, amidated PHSCN peptide, Ac-PHSCN-NH 2 [2] , emerged as an invasion inhibitor during structure activity studies of the invasioninducing PHSRN peptide [8] . The PHSRN sequence of the fibronectin cell binding domain [9, 10] is uniquely an a5b1 ligand, interacting with a specific region of the a5 subunit. In addition to preventing prostate cancer cell invasion and metastasis [8] , Ac-PHSCN-NH 2 is also a potent inhibitor of microvascular endothelial cell invasion and angiogenesis [1] . Systemic Ac-PHSCN-NH 2 prevented disease progression for prolonged periods in several preclinical models, and in phase 1 clinical trial [2, [11] [12] [13] [14] . Thus, Ac-PHSCN-NH 2 is a promising lead compound for targeted therapy of prostate cancer invasion and metastasis.
To increase its potency, we attached eight Ac-PHSCNGGK peptide moieties to the N-termini of the multiantigenic peptide (MAP) polylysine dendrimer. We report that this creates a significantly more potent inhibitor of a5b1 integrinmediated DU 145 and PC-3 human prostate cancer cell invasion and matrix metalloproteinase 1 (MMP-1) induction in vitro, and of extravasation and lung colony formation in vivo in athymic nude mice. Furthermore, Chou-Talalay analysis of the in vitro invasion assay data suggests that inhibition by the PHSCN dendrimer is highly synergistic. We also report that the PHSCN dendrimer prevents DU 145 and PC-3 cell extravasation into the lungs of athymic, nude mice over 100-fold more effectively than the PHSCN peptide, and that a single pretreatment with the PHSCN dendrimer greatly reduces lung colony formation.
Materials and methods
Cell lines and cell culture DU 145 [15] and PC-3 [16] metastatic human prostate cancer cells were obtained from American Type Culture Collection (Manassas, VA). They were cultured as recommended, and frozen in liquid N 2 in aliquots within 2 months of receipt. Single aliquots were subsequently resuscitated as needed, and cultured as recommended. No aliquot of cells was cultured for more than 4 months, and the morphologies of all cultures were routinely checked by phase contrast microscopy. Growth curves of all cultures were always recorded, and checked for consistency. For all assays in serum-free (SF) medium, DU 145 and PC-3 cells were first serum-starved overnight.
Peptide and MAP synthesis N-terminal acetylated, C-terminal amidated PHSRN, PHSCN, and HSPNC peptides (Ac-PHSRN-NH 2 , Ac-PHSCN-NH 2 , and Ac-HSPNC-NH 2 ) were synthesized, their structures confirmed, and their purities assessed as described [1-3, 8, 17] . Their purities were as follows: Ac-PHSRN-NH 2 , 97%; Ac-PHSCN-NH 2 , 98%; Ac-HSPNC-NH 2 , 91%.
N-terminal acetylated PHSCN and HSPNC MAPs were synthesized by covalently attaching peptide C-termini to the N-termini of a polylysine dendrimer, 8 core MAP (Sigma-Aldrich, Saint Louis MO). MAPs were synthesized by Fmoc solid phase synthesis in a manual procedure with reaction monitoring by Ninhydrin test [18] , to allow for complete coupling of each amino acid. Quality control of the MAPs was performed by amino acid analysis [19] , followed by Edman sequencing and preview analysis to reveal any deletions in the sequences [20] . Dendrimer purities were estimated to be as follows: Ac-PHSCNGGK-MAP, 94%; Ac-HSPNCGGK-MAP, 97% (not shown). The MAPs were also evaluated by MALDI for the expected mass of the fully populated dendrimer. The spectra showed the expected mass for the complete MAP and very little evidence of incomplete synthesis (not shown).
PHSCN and HSPNC peptides to be attached to polylysine dendrimers or ovalbumin were synthesized with two glycines and a lysine (GGK) on the C-terminal end (PHSCNGGK or HSPNCGGK) to provide a spacer and an attachment site for labeling. Ac-PHSCNGGK-NH 2 and Ac-HSPNCGGK-NH 2 had functional characteristics identical to Ac-PHSCN-NH 2 and Ac-HSPNC-NH 2 , respectively (not shown). PHSCN-coupled ovalbumin (Ac-PHSCNGGK-Ova) was synthesized by coupling the PHSCNGGK C-terminus to ovalbumin with an attached EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydro chloride) crosslinker (ThermoFisher Scientific, Waltham MA), according to established procedures [21] . Ac-PHSCNGGKOva purity was 90%.
In vitro invasion assays
Naturally occurring basement membranes were utilized as in vitro invasion substrates, as described [1-3, 8, 17] . For assays evaluating the effects of blocking anti a5b1 MAb on invasion, serum starved DU 145 or PC-3 cells were incubated for 30 min on ice in serum-containing medium with 10 lg/ml or 50 lg/ml anti a5b1 MCA1187 function blocking monoclonal antibody (MAb; Serotec, Oxford, England) [22] , prior to placement on basement membranes. For assays evaluating the effects of inhibitors on PHSRNinduced invasion in SF medium, the concentration of Ac-PHSRN-NH 2 was 0.1 lg per ml/20,000 cells in an assay volume of 1 ml. All cells were serum starved prior to addition of 10% FBS or Ac-PHSRN-NH 2 . Peptides or dendrimers were prebound to cells prior to placement on basement membranes. Data, mean invasion percentages, were analyzed using Graphpad Prism 5 software (San Diego, CA) as a function of log (inhibitor) versus normalized data, variable slope.
Data analysis
Data were analyzed by the Combination Index (CI) method of Chou-Talalay [23] , as described in [24] . The analysis was based on the multiple drug effect equation derived from the median effect principle of the mass-action law. The median-effect equation, y = log(f a /f u ), with respect to x = log(dose), defines the dose and effect relationship in the absence of reaction rate constants, where f a is the fraction of cells affected (invasion-inhibited), and f u is the fraction of cells unaffected (invaded). The x intercept represents the IC50 value. CI and DRI values were determined assuming that the monomer represents the single dose, and the dendrimer (with 8 PHSCNGGK moieties) represents the combinatorial dose.
MMP-1 activity assays
Effects of Ac-PHSCNGGK-MAP, Ac-HSPNCGGK-MAP, or Ac-PHSCN-NH 2 on MMP-1 activities secreted by adherent cells were analyzed as described [17] . Treatment groups were stimulated with 5 ml 10% FBS or SF medium containing 250 lg per 1,000,000 cells Ac-PHSRN-NH 2 for 24 h after pretreatment with Ac-PHSCN-NH 2 , Ac-PHSCNGGK-MAP, or Ac-HSPNCGGK-MAP at 250 lg per 1,000,000 cells for 1 h. Media from the treated cells were removed for analysis. Human MMP-1 ELISA Kit (RayBiotech, Inc., Norcross GA) was used to quantitate MMP-1 activity, according to manufacturer's instructions. Data are presented as means ± SD, and results were analyzed using Student's t test.
Fluorescent DiI labeling of cells
Confluent DU 145 or PC-3 cells were washed with Hanks Buffered Salt Solution (HBSS; Life Technologies, Grand Island NY), harvested with 0.25% trypsin/1% EDTA (Life Technologies), rewashed in HBSS, and red fluorescently labeled in 6 ml SF medium with 25 ll of the lipophilic carbocyanine vital dye DiI, 1,1 0 -dilinoleyl-3,3,3 0 3 0 -tetramethylindocarbocyanine perchlorate (Invitrogen), for 20 min in dark at 37°C, as described [25, 26] . DiI has been utilized as a vital dye in numerous studies, for example, to define neural crest invasive/migratory pathways in developing embryos [27] . Cells were pelleted at 1000 RPM for 2 min, prior to resuspension in 6 ml of medium, and recovery for 72 h.
Extravasation in the lungs athymic mice
To compare the effects of blocking anti a5b1 MAb on the accumulation of labeled DU 145 or PC-3 cells in lung tissue after intravenous injection, DiI labeled DU 145 or PC-3 cells were incubated for 30 min on ice with 10 lg/ml or 50 lg/ml anti a5b1 MCA1187 function blocking monoclonal antibody (MAb; Serotec, Oxford, England), as described [22] . A total of 10,000 pretreated cells in 0.1 ml HBSS were injected into the tail vein of each 8-week, nude athymic mouse (Jackson Laboratories, Bar Harbor ME). All mice were euthanized 24 h later, and their lungs removed and thoroughly rinsed with phosphate buffered saline (PBS) prior to fixation with 4% paraformaldehyde in PBS overnight at 4°C. Following fixation, lungs were rinsed at room temperature in PBS, placed in 20% sucrose overnight at 4°C. The samples were cryoprotected by submerging in O.C.T. (Optimal Cutting Temperature): 20% sucrose mixture (VWR, Batavia IL) overnight at 4°C, prior to freezing and storing at -80°C. Frozen lungs were sectioned with a thickness of 10 lm with a Zeiss Cryostat (M550). All slides were sealed with VECTASHIELD mounting medium with DAPI (VECTOR Laboratories, Burlingame CA). Sections were examined at 400-fold magnification with a Zeiss Scanning Laser Confocal microscope (LSM510), as previously described [28] .
To compare Ac-PHSCNGGK-MAP, Ac-PHSCN-NH 2 , and Ac-HSPNCGGK-MAP as inhibitors of cellular accumulation in the lung tissue, DiI-labeled DU 145 or PC-3 cells were prebound with appropriate concentrations of dendrimer or peptide in HBSS and incubated at 37°C for 10 min. The concentrations used for prebinding were as follows: Ac-PHSCNGGK-MAP: 10, 1, 0.1, or 0.01 ng/ml; Ac-PHSCN-NH 2 : 100, 10, 1, or 0.1 ng/ml; Ac-HSPNCGG-MAP: 100 ng/ml. Nude mice (Jackson Laboratories) received an equivalent intravenous dose of dendrimer or peptide (0.0005-5.0 lg/kg) via tail vein, immediately prior to intravenous injection of 10,000 DiI labeled, dendrimer-or peptide-prebound DU 145 or PC-3 cells per mouse. Labeled, pretreated cells were intravenously injected in 0.1 ml HBSS, and mice euthanized 24 h later, as described above. Lungs were removed, rinsed, fixed, treated, and frozen as described above. Lungs were sectioned and sections analyzed by confocal microscopy, as described above. Data are presented as means ± SEM of 10 mice per group.
To determine precisely what fractions of DU 145 and PC-3 cells were intravascular or extravascular, cells and mice were treated and sections made as described above. Sections were immunostained with rat anti mouse PECAM-1 (platelet endothelial cell adhesion molecule-1) monoclonal antibody (Millipore, Temecula CA) [29] , and FITC-conjugated secondary antibody (Jackson Laboratories, Bar Harbor, Maine). Sections were scored as described above, such that DU 145 and PC-3 cells surrounded by at least 75% of their circumference with anti PECAM staining were judged to be intravascular. Cells surrounded by less anti PECAM staining were judged to be extravascular, and hence to have completed extravasation.
Lung colony formation assays
To verify the enhanced potency of Ac-PHSCNGGK-MAP as an inhibitor of lung colony formation, suspended, DiI labeled DU 145 or PC-3 cells were briefly prebound with 10 ng/ml Ac-PHSCNGGK-MAP, 10 ng/ml and 100 ng/ml Ac-PHSCN-NH 2 , or 100 ng/ml Ac-HSPNCGGK-MAP. Eight week-old, nude mice (Jackson Laboratories) received one systemic pretreatment with the appropriate peptide or dendrimer concentration by tail vein injection, as described above. Immediately after pretreatment, DU 145 or PC-3 cells, prebound with dendrimer or peptide, or with HBSS only, were injected into tail veins. Mice received no other systemic treatments. Six weeks after injection, mice were euthanized, and lungs were removed, fixed, prepared, and stored as above.
Sections of 10 lm thickness were cut with a Zeiss cryostat as previously described: 20 sections were cut from each lung in all mice of each treatment group, at 200 lm intervals. Thus, a total thickness of 4 mm was analyzed from each lung. Sections were stained with monoclonal, FITC-conjugated anti b-actin antibody (Chemicon, Temecula CA) and scored at 400-fold magnification, based on the retention of DiI red fluorescence by the prostate cancer cells, as described for other cancer types [25, 26] . DU 145 and PC-3 colonies were scored only if they contained more than 50 cells, according to established criteria for colony formation [30] [31] [32] . Data are presented as mean numbers of colonies per lung ± SEM of 10 mice per group.
Clonogenic assays
Clonogenic survival assays were performed as described [33] .
Results
Inhibition of DU 145 and PC-3 accumulation in lungs by pretreatment with blocking anti a5b1 MAb
We evaluated the potential role of a5b1 integrin in extravasation by prebinding suspended DU 145 and PC-3 cells to blocking anti a5b1 MCA1187 MAb prior to intravenous injection into mouse tail veins. As shown in Fig. 1a -b, MCA1187 pretreatment reduced the numbers of DU 145 and PC 3 cells in lung tissue by six-to nine-fold, consistent with the hypothesis that a5b1 plays a key role in the invasive stage of extravasation and encouraging the investigation of a5b1 inhibitors.
Invasion inhibition by the PHSCN polylysine dendrimer, Ac-PHSCNGGK-MAP
To compare inhibitory potencies of Ac-PHSCNGGK-MAP and Ac-PHSCN-NH 2 for basement membrane invasion, serum-starved DU 145 and PC-3 cells were prebound to various concentrations of Ac-PHSCNGGK-MAP or Ac-PHSCN-NH 2 , or to maximal concentrations of the appropriate specificity controls: Ac-HSPNCGGK-MAP or Ac-HSPNC-NH 2 , prior to invasion induction and placement on basement membranes. We have identified plasma fibronectin (pFn) as the invasion-inducing protein in serum, and shown that its PHSRN sequence is sufficient for invasion induction in human breast and prostate cancer cell lines [2, 3, 8, 17] , and in normal microvascular endothelial cells, epithelial cells, and fibroblasts [1, 8] . Thus, we compared the inhibitory potencies of Ac-PHSCNGGK-MAP and Ac-PHSCN-NH 2 for both serum-induced and PHSRN-induced, SF invasion by DU 145 and PC-3 cells. Since Ac-PHSCNGGK-MAP displays the PHSCN sequence on a significantly larger molecule (7575 vs. 598 Da), we also evaluated the effect on invasion inhibitory potency of a modified protein, resulting from coupling a single Ac-PHSCNGGK sequence to ovalbumin (45.0 kDa), to make Ac-PHSCNGGK-Ova (45.9 
kDa).
To analyze the results of in vitro invasion assays, we constructed Hill-Slope plots, as shown in Fig. 2 . The nM concentrations of the PHSCN dendrimer and PHSCN peptide, and the HSPNC dendrimer and PHSCN-Ovalbumin negative controls were plotted versus the mean percentages of DU 145 and PC-3 cells invaded, after stimulation with 10% FBS, or with 100 ng/ml Ac-PHSRN-NH 2 , under serum-free conditions. Irrespective of whether a5b1 mediated invasion was stimulated by the presence of serum or by the PHSRN peptide under serum-free conditions, the PHSCN dendrimer was two to three orders of magnitude more potent as an invasion inhibitor than the PHSCN peptide. High concentrations of HPSNC dendrimer failed to block invasion. Also, putting a single PHSCNGGK moiety on a larger molecule, ovalbumin, failed to increase its potency significantly. These data were also plotted according to the median-effect equation, y = log(f a /f u ), with respect to x = log(dose), where f a is the fraction of cells affected (invasion-inhibited), and f u is the fraction of cells unaffected (invaded). This analysis indicated a linear coefficient (r) value [ 0.97, suggesting conformity to the mass-action law principle (not shown).
The IC 50 values were calculated from the Hill-Slope plots (Fig. 2) were similar to those derived from the median-affect equation, and are listed in units of nM in Table 1 . As shown by the Dose Reduction Index (DRI) The Combination Index (CI) and the DRI values, shown in Table 1 , allow determination of whether the 8 PHSCN moieties on the dendrimer result in an additive or a synergistic increase in invasion inhibitory potency. Synergism is demonstrated by CI \ 1 and DRI [ 1, and additive effects are indicated by CI C 1 and DRI C 1 [23] . Thus in combination, the CI and DRI values listed in Table 1 for both cell lines show the increased efficacy of the PHSCN dendrimer, and indicate that its 8 PHSCN moieties interact synergistically to block invasion for in vitro assays.
Inhibition of serum-or PHSRN-induced MMP-1 secretion by Ac-PHSCNGGK-MAP
The induction of MMP-1 secretion and MMP-1-dependent invasion by the PHSRN/a5b1 interaction [1] [2] [3] 17] , and the inhibition of a5b1-mediated induced MMP-1 secretion in DU 145 cells by Ac-PHSCN-NH 2 [3] , suggested that Ac-PHSCNGGK-MAP would be a significantly more potent inhibitor of a5b1-mediated MMP-1 induction by serum, or by Ac-PHSRN-NH 2 . Thus, adherent DU 145 and PC-3 cells were serum-starved overnight prior to inhibitor pretreatment and stimulation with medium containing 10% FBS, or with SF medium containing Ac-PHSRN-NH 2 as in prior studies [3, 17] . Inhibitors of serum-or Ac-PHSRN-NH 2 -induced MMP-1 secretion included Ac-PHSCN-NH 2 , Ac-PHSCNGGK-MAP, or the Ac-HSPNCGGK-MAP specificity control, all at the same mass concentration (250 lg/1,000,000 cells) as Ac-PHSRN-NH 2 and are shown in Fig. 3 .
Considering molar concentration instead of mass/volume, Ac-PHSCNGGK-MAP (at 33 lM) was a 65-650-fold more potent inhibitor of a5b1-mediated MMP-1 secretion by DU 145 and PC-3 cells than Ac-PHSCN-NH 2 (at 418 lM), whether induction was by 10% FBS or by Ac-PHSRN-NH 2 .
Reduction of DU 145 or PC-3 cells in the lungs of nude mice after prebinding Ac-PHSCNGGK-MAP or Ac-PHSCN-NH 2 The enhanced potency of Ac-PHSCNGGK-MAP relative to Ac-PHSCN-NH 2 observed in vitro invasion assays with naturally occurring basement membranes suggested that Ac-PHSCNGGK-MAP should be a more potent inhibitor of intravenous DU 145 or PC-3 cell accumulation in mouse lungs. To compare efficacies of Ac-PHSCNGGK-MAP and Fig. 4a-b as a function of concentration (nM). Pretreatment with the scrambled sequence control dendrimer (100 ng/ml Ac-HSPNCGGK-MAP) resulted in a mean of 1186 (±148) or 890 (±39) when the same number of suspended DU 145 cells or PC-3 cells were injected, respectively; indicating little or no effect. A typical example of the data used to obtain these results is shown in Fig. 4c . Sections containing extravasated DU 145 cells had a very similar appearance (not shown).
The IC50 values were determined from the extrapolated x-intercept (Fig. 4a-b) and the DRI and CI values were calculated, as summarized in Table 2 . The increased potency of Ac-PHSCNGGK-MAP over the Ac-PHSCN-NH 2 peptide (800-fold) for preventing extravasation was similar to that found for in vitro invasion assays with naturally occurring basement membranes. Furthermore, the DRI and CI values shown in Table 2 indicate that extravasation inhibition was highly synergistic.
The complete process of extravasation requires that blood-borne cells cross the endothelial cell layer and its Clin Exp Metastasis (2010) Extravasation is a key step in metastasis formation [5, 31] . Based on its increased anti-invasive potency, Ac-PHSCNGGK-MAP should be a more potent inhibitor of lung colony formation than Ac-PHSCN-NH 2 , after intravenous injection of mice with pretreated DU 145 or PC-3 cells.
Because others have previously shown that both DU 145 and PC-3 cells, when intravenously injected into athymic mice, colonize the lungs and efficiently grow into macroscopic metastatic colonies [34, 35] , we utilized these cell lines to compare the effects of Ac-PHSCNGGK-MAP and Ac-PHSCN-NH 2 on lung colony formation. We found that pretreatment with 10 ng/ml (1.32 nM) Ac-PHSCNGGK-MAP reduced DU 145 lung colony formation by 5.8-fold, relative to untreated controls; whereas, pretreatment with 10 ng/ml (17 nM) Ac-PHSCN-NH 2 had a less inhibitory effect: reducing DU 145 lung colonies by 2.4-fold (Fig. 6a) . Pretreatment with a tenfold higher concentration of Ac-PHSCN-NH 2 (100 ng/ml, 170 nM) reduced DU 145 lung colony formation by 5.9-fold, similar to the reduction observed after pretreatment with 10 ng/ml (1.32 nM) Ac-PHSCNGGK-MAP. No significant reduction in lung colony formation was obtained by pretreatment of DU 145 cells with Ac-HSPNCGGK-MAP, at 100 ng/ml (170 nM). As shown in Fig. 6b , much the same results were obtained for PC-3 cells. The similar inhibitory responses of the doses 10 ng/ml (1.32 nM) Ac-PHSCNGGK-MAP and Ac-PHSCN-NH 2 (100 ng/ml, 170 nM) for both cell lines are separated by approximately 2 orders of magnitude in concentration (Fig. 6a-b) . This allows calculation of an approximate DRI of 128.
Since only growing micrometastases are functionally relevant, the total number of cells in each micrometastasis was determined for each treatment group shown in Fig. 6 . Each micrometastasis included in the totals contained from 50 to 200 cells (not shown), similar to criteria previously employed by others [30] [31] [32] .
Because it was possible that inhibition of lung colony formation by the PHSCN dendrimer might have been due to reduction in survival of the extravasated DU 145 and PC-3 cells, the effects on clonogenic survival of several Ac-PHSCNGGHK-MAP concentrations were compared to elevated concentrations of Ac-HSPNCGGK-MAP and Ac-PHSCN-NH 2 . The Ac-PHSCNGGK-MAP and Ac-PHSCN-NH 2 concentrations tested (50-200 lg/ml) were 500-to 20,000-fold higher than the concentrations used in pretreatments to prevent extravasation and inhibit lung colony growth (0.01-0.1 lg per ml), and were present continuously throughout the period of clonogenic growth. As shown in Fig. 7a , Ac-PHSCNGGK-MAP failed to reduce DU 145 clonogenic survival significantly, as compared with equal concentrations of the Ac-HSPNCGGK-MAP or Ac-PHSCN-NH 2 . Thus, inhibition of DU 145 survival in lung colonies in vivo by Ac-PHSCNGGK-MAP pretreatment is a very unlikely explanation for the reduced lung colonies observed. As shown in Fig. 7b , elevated concentrations of the PHSCN dendrimer (100-200 lg per ml) may have reduced PC-3 clonogenic survival by approximately twofold, when compared to the HSPNC dendrimer. However, the concentrations of PHSCN dendrimer required to achieve this effect were 2,000-to 20,000-fold higher than the concentrations used to prevent extravasation and limit lung colony growth. Thus, reduction of PC-3 lung colonies in vivo through inhibition of clonogenic survival by PHSCN dendrimer pretreatment is also unlikely.
Discussion
Prostate cancer is the most common non-skin malignancy, and the third leading cause of cancer deaths in men [36, 37] . About 39% of men with prostate cancer will develop metastatic disease at some point [38] . Metastatic prostate cancer is presently incurable, and most patients with this disease succumb over a period of months to years [39] . Lung metastasis is found in an average of 40% of metastatic prostate cancer patients at autopsy, with reports ranging from 16 to 56% [40] . Prostate cancer lung metastasis can consist of multiple nodules, diffuse lymphatic disease, or grossly normal lungs, exhibiting micrometastases only [41] . However, it can also have serious consequences, like malignant pleural effusion [42] . Because a5b1 integrin fibronectin receptor-mediated invasion by microvascular endothelial cells to promote tumor growth, and by prostate cancer cells to cause widespread dissemination are key features of metastatic disease progression, we have pursued it as a therapeutic target in our previous studies [1] [2] [3] . Here, we have shown that attaching 8 PHSCNGGK peptide moieties to a polylysine dendrimer increases the invasion-inhibitory potency of the PHSCN sequence by 131-to 1908-fold for a5b1-mediated invasion in vitro, and Chou-Talalay analysis suggests that invasion inhibition is highly synergistic. Consistent with the requirement for MMP-1 in microvascular endothelial cell and prostate cancer cell invasion in vitro [1, 3] , and with recent reports that MMP-1 promotes prostate tumor growth and metastasis, and that overexpression of MMP-1 in prostate cancer cells increases invasion [43] , we also observed that the PHSCN dendrimer was 65-650-fold more potent inhibitor of a5b1-mediated MMP-1 activity than the PHSCN peptide.
Moreover, we also found that the PHSCN dendrimer is about 800-fold fold more potent than the PHSCN peptide at blocking prostate cancer cell extravasation into lung tissue, and Chou-Talalay analysis also suggests that inhibition extravasation inhibition by the PHSCN dendrimer is highly synergistic. Furthermore, approximately 80% of the prostate cancer cells, found in lung tissue after prebinding to PHSCN dendrimer and intravenous injection, still appeared to by largely surrounded by anti PECAM-stained endothelial cells, suggesting that, while they may have adhered to the luminal surfaces of endothelial cells, only about 20% actually succeeded in completing the process of extravasation to enter the surrounding lung tissue. In contrast, less than 20% of untreated prostate cancer cells appeared to remain inside the lung vasculature; over 80% of them appeared to have completed extravasation.
Finally, a single pretreatment with PHSCN dendrimer, followed by a single, equivalent systemic dose, was 100-fold more effective than the PHSCN peptide at reducing lung colony formation, and no significant reduction in lung colony formation was obtained by pretreatment with HSPNC dendrimer. Moreover, a single PHSCN dendrimer treatment of 1 ng per mouse reduced lung colony formation by sixfold, relative to untreated controls. In contrast, daily administration of 0.5 mg of the 8-mer YIGSR polylysine dendrimer was required to reduce B16F10 melanoma lung colony formation by a similar extent [44] , suggesting that invasion may be a more sensitive therapeutic target for antimetastatic drugs than adhesion.
As indicated by clonogenic assays performed in the presence of greatly elevated (2-4 orders of magnitude higher) concentrations, there was no significant reduction of DU 145 clonogenic survival by either the PHSCN dendrimer or peptide, and only a slight reduction in PC-3 clonogenic survival. Thus, inhibition of DU 145 or PC-3 survival in lung colonies in vivo by PHSCN dendrimer pretreatment is a very unlikely explanation for the reduced lung colonies observed.
When unchecked by normal regulatory mechanisms, the regulatory pathways initiated by a5b1 integrin may give rise to the progressive growth and invasion observed in metastatic prostate cancer. For example, the interaction of a5b1 with the PHSRN sequence of the fibronectin cell binding domain is sufficient to induce interstitial collagenase expression and invasion by microvascular endothelial cells [1] and metastatic prostate cancer cells [2, 3] , as well as breast cancer cells [17] and normal epithelial cells and fibroblasts [8] . Because fibronectin is found in all body fluids, proper regulation of a5b1-mediated invasion is very important. This is accomplished by another integrin fibronectin receptor, a4b1. When fibronectin is intact, a4b1 integrin interacts with the LDV sequence of the fibronectin connecting segment, LHGPEILDVPST, to repress a5b1-mediated interstitial collagenase expression [45] , and invasion induction [17] . Fragmentation of fibronectin by urokinase plasminogen activator, which also functions in clot dissolution (reviewed in [46] ), gives rise to a5b1-mediated invasion during wound healing [47, 48] . Thus, an important attribute of a5b1-induced invasion in normal a5b1
? , a4b1 ? cells is its regulation by a4b1 integrin. Although still expressing abundant surface a5b1, many metastatic prostate and breast cancer cell lines have low levels of surface a4b1, relative to mammary and prostate epithelial cells [49, 50] . Loss of surface a4b1, which can result from oncogene overexpression in transformed mammary epithelial cells [50] , has been shown to cause constitutive invasiveness in the presence of the abundant pFn of blood, lymph, and interstitial fluid [51, 52] in metastatic prostate cancer and breast cancer cell lines [2, 17, 50, 53, 54] . Thus, systemic therapy with an agent, like a PHSCN peptide derivative, that effectively targets the activated a5b1 integrins of tumors, without affecting the a5b1 receptors of healthy tissues, could represent potentially effective therapy for patients with metastatic prostate cancer.
The rationale for employing PHSCN-dendrimers as improved therapeutic agents is that their polyvalency will enhance the affinity of their interactions with their target protein, the a5b1 integrin. There are many examples of the ability of multimeric peptides to enhance binding affinity. For example, a peptide complementary to a specific region of endothelin exhibited a binding affinity that was significantly greater when it was synthesized as a MAP peptide [55] . Peptide dendrimers are also used as inhibitors of increased potency. For example, peptide dendrimers have been used to inhibit the entry of malaria parasites into hepatocytes [56] . In another example, a peptide dendrimer based on an 8 amino acid sequence from gp120, the HIV-1 surface envelope glycoprotein, has been shown to inhibit HIV-1 infection of both CD4
? and CD4 -cells [57, 58] . Lymph nodes, bone, lung, and liver are the most frequent sites of prostate cancer metastasis. Because lung metastasis occurs in over 40% of prostate cancer patients with hematogenous metastatic disease [38] , this study focused on targeting the a5b1 integrin fibronectin receptors of prostate cancer cells to reduce their extravasation into lung tissue, thereby limiting lung colony formation. However, bone is also an extremely important site for prostate cancer metastasis [59] , and cooperation between a5b1, a3b1, and amb3 integrins is thought to be necessary for the docking of PC-3 and DU 145 cells to stimulated human umbilical vein endothelial cells [60] . Thus, future studies will evaluate the effects of the PHSCN dendrimer on adhesion to endothelial cells, the initial step in extravasation, and will compare the effects of systemic PHSCN dendrimer with PHSCN peptide on prostate cancer cell bone metastasis in athymic mice.
